Sales up by 11% for quarter ended December 31, 2022
Procter & Gamble Health Limited today announced its financial results for the quarter ended December 31, 2022. The company has recorded a robust performance with sales of ₹ 304.7 crores for the quarter ended December 31, 2022, vs ₹ 273.3 crores a year ago, up by 11%. The Profit After Tax (PAT) was ₹ 76.8 crores vs ₹ 44.9 crores a year ago, supported by improved margin through portfolio premiumisation, healthy mix and optimization of expenses. Sales for the six-month period ending December 31, 2022, are ₹ 596.6 crores, vs ₹ 541.0 crores a year ago, up by 10%. Profit After Tax for same period is ₹ 140.5 crore vs ₹ 100.2 crore a year ago up by 40%.
Mr. Milind Thatte, Managing Director, P&G Health India, said, “We delivered sales of ₹ 596.6 crores for half year, up by 10% over year ago, despite macroeconomic challenges, including rising inflation and high input costs. We have witnessed consistent growth over the second quarter and an overall promising first half of the year. Our encouraging financial results in the second quarter can be attributed to our core belief of bringing care closer to patients through innovative approaches. With continued focus on the health and wellness of patients and consumers, we launched Polybion A injection, a new and improved formulation, which can help doctors effectively manage the recovery of their patients, while giving a good boost to energy levels. On World Iron Deficiency Day, P&G Health in partnership with FOGSI (The Federation of Obstetric and Gynecological Societies of India) initiated the ‘Na Na Anemia Bus Yatra’, a 40-day Bus Yatra across 20 cities and 5 states to create awareness on Iron Deficiency Anemia. As a leader in Nerve Health and a partner to International Diabetes Federation, on World Diabetes Day 2022, P&G Health launched a large-scale collective awareness effort on Peripheral Neuropathy which was recognized among India’s top diabetes campaigns by Obesity International.
The quarter also saw recognition of our Brand and Citizenship efforts through the prestigious awards – (1) CIMS Annual Wellness and Nutrition Awards ‘Trusted Brand of the Year’ (Polybion), (2) CIMS Annual Wellness and Nutrition Awards ‘Health and Wellness Product of the Year’ (Neurobion), (3) India Health & Wellness Awards ‘Gold’ for Health Awareness Campaign of the year (Neurobion ‘Feel Life’ and Livogen ‘LetHerBreakFree’) and (4) India Health & Wellness Awards ‘Silver’ (SEHAT Public Health Initiative). This has further encouraged us in our commitment to serve Indian consumers and empower them to live healthier and more vibrant lives,” he added.
About Procter & Gamble Health Limited: Procter & Gamble Health Limited is one of India’s largest VMS companies manufacturing and marketing vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. Please visit www.pghealthindia.com for the latest news and information about Procter & Gamble Health Limited and its brands.
About Procter & Gamble: P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Ambi Pur®, Ariel®, Gillette®, Head & Shoulders®, Olay®, Oral-B®, Pampers®, Pantene®, Tide®, Vicks®, and Whisper®. P&G operates in approximately 70 countries worldwide.
